.Nature Medicine, Released online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) procedure of patients along with HER2+ state-of-the-art bosom cancer cells and active or secure mind metastases showed regular intracranial task as well as systemic efficiency of T-DXd.